Premium
PCNA‐associated factor P15 PAF , targeted by FOXM1, predicts poor prognosis in high‐grade serous ovarian cancer patients
Author(s) -
Jin Chengjuan,
Liu Zhaojian,
Li Yingwei,
Bu Hualei,
Wang Yu,
Xu Ying,
Qiu Chunping,
Yan Shi,
Yuan Cunzhong,
Li Rongrong,
Diao Nannan,
Zhang Zhiwei,
Wang Xiangxiang,
Liu Lidong,
Kong Beihua
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31800
Subject(s) - pi3k/akt/mtor pathway , ovarian cancer , cancer research , foxm1 , protein kinase b , autophagy , metastasis , cancer , biology , signal transduction , oncology , apoptosis , medicine , microbiology and biotechnology , cell cycle , biochemistry
Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer. In this study, we demonstrated that P15 PAF (KIAA0101) was significantly upregulated in high‐grade serous ovarian cancer (HGSOC) and that high KIAA0101 expression was associated with poor prognosis. FOXM1 transcriptionally activated KIAA0101 to drive proliferation and metastasis of ovarian cancer cells. KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin‐induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance. Thus, KIAA0101 was closely related to the FOXM1 and PI3K/AKT/mTOR signaling pathways. Collectively, these findings provide insights into the mechanisms of poor prognosis of ovarian cancer and have implications for the development of both predictive and therapeutic biomarkers for the treatment of ovarian cancer.